GMG-3 GMG-4 and GMG-6 polynucleotides and polypeptides and uses thereof
View Patent ↗The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GMG-3, GMG-4, Cluster 1, GMG-6A, or GMG-6B polypeptides have been identified that are beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
1. A method of treating an obesity-related disease or disorder comprising administering to an individual a composition comprising a polypeptide or biologically active fragment thereof, wherein said polypeptide or biologically active fragment thereof comprises all or part of a C-terminal globular C1q homology domain and wherein said polypeptide comprises SEQ ID NO: 2 or comprises a biologically active fragment of SEQ ID NO: 2.
2. The method of claim 1 , wherein said obesity-related disease or disorder is selected from the group consisting of:
(a) obesity;
(b) impaired glucose tolerance;
(c) insulin resistance;
(d) Syndrome X; and
(e) Type II diabetes.
3. The method of claim 2 , wherein said obesity-related disease or disorder is obesity.
4. The method of claim 2 , wherein said obesity-related disease is impaired glucose tolerance.
5. The method of claim 2 , wherein said obesity-related disease is insulin resistance.
6. The method of claim 2 , wherein said obesity-related disease is Syndrome X.
7. The method of claim 2 , wherein said obesity-related disease is Type II diabetes.
8. The method of claim 1 , wherein said biologically active polypeptide fragment is selected from the group consisting of:
(a) amino acids 20-333 of SEQ ID NO: 2;
(b) amino acids 188-333 of SEQ ID NO: 2;
(c) amino acids 191-333 of SEQ ID NO: 2;
(d) amino acids 193-333 of SEQ ID NO: 2; and
(e) amino acids 252-317 of SEQ ID NO: 2.
9. The method of claim 8 , wherein said biologically active polypeptide fragment comprises amino acids 20-333 of SEQ ID NO: 2.
10. The method of claim 8 , wherein said biologically active polypeptide fragment comprises amino acids 188-333 of SEQ ID NO: 2.
11. The method of claim 8 , wherein said biologically active polypeptide fragment comprises amino acids 191-333 of SEQ ID NO: 2.
12. The method of claim 8 , wherein said biologically active polypeptide fragment comprises amino acids 193-333 of SEQ ID NO: 2.
13. The method of claim 8 , wherein said biologically active polypeptide fragment comprises amino acids 252-317 of SEQ ID NO: 2.
14. The method of claim 1 , wherein said polypeptide or biologically active fragment thereof is administered prior to the onset of clinical symptoms associated with said obesity-related disease or disorder.